Avacta Appoints Mats Blom Audit Chair
Analysis based on 7 articles · First reported Sep 14, 2026 · Last updated Sep 15, 2026
The appointment is a routine governance change for a small-cap AIM-listed biotech and is unlikely to move broader markets, though it modestly supports Avacta Group shares by strengthening board financial oversight. Investors will focus on the company's clinical catalysts, notably AVA6103 FOCUS-01 data expected in late 2026, rather than on the board reshuffle itself.
Avacta Group Therapeutics, a clinical-stage biopharmaceutical company listed on AIM under ticker AVCT, announced on September 14, 2026 the appointment of seasoned biotechnology finance executive Mats Blom to its Board of Directors as a non-executive director and Chair of the Audit Committee. As part of this board evolution, current Audit Committee Chair Paul Fry indicated his intention to step down from the Board effective September 30, 2026, allowing for an orderly transfer of his responsibilities to Blom. CEO Christina Coughlin welcomed Blom, citing his deep financial expertise and extensive experience in the biotechnology and life sciences sectors across the US and Europe as instrumental to advancing the company's pre|CISION tumor-activated oncology delivery platform and delivering on clinical and strategic milestones. Blom, aged 61, has held CFO roles at several life sciences companies including Zealand Pharma A/S from 2010 to 2019, where he oversaw its Nasdaq listing and earlier IPO on Nasdaq OMX Copenhagen, as well as at Active Biotech and Anoto Group. He currently chairs the Board of Egetis Therapeutics AB and serves on the Boards of GT Biopharma AB and privately held Pephexia Therapeutics ApS. He was previously a Board member at Nasdaq-listed Coya Therapeutics and held positions at NorthSea Therapeutics USA Inc, Modus Therapeutics and Swedish Orphan International. Earlier in his career he was a management consultant at Capgemini and Ernst & Young, and holds a BA from Lund University and an MBA from IESE Business School. Avacta Group shares traded up 1.99% at GBp 77 on the Aquis Stock Exchange following the announcement. The company anticipates releasing initial clinical data for AVA6103 from the FOCUS-01 trial in the late second half of 2026 and plans payload and clinical candidate selection for the AVA6207 program in the second half of 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard